West Pharmaceutical Services Set to Release Q1 2025 Earnings Soon

West Pharmaceutical Services, Inc. (WST), located in Exton, Pennsylvania, specializes in designing, manufacturing, and selling containment and delivery systems for injectable drugs and healthcare products. With a market capitalization of $14.7 billion, the company is known for its innovative technologies that include packaging components, research and development of drug delivery systems, and a range of contract laboratory services. WST is anticipated to announce its fiscal first-quarter earnings for 2025 before the market opens on Thursday, April 24.

Analysts forecast that WST will report earnings of $1.30 per share on a diluted basis, representing a decrease of 16.7% from the $1.56 per share earned in the same quarter last year. WST has performed well against consensus estimates, beating expectations in three out of the last four quarters, although it missed once.

Annual Earnings Expectations and Future Projections

For the full year, analysts are predicting WST’s earnings per share (EPS) to be $6.44, a decline of 4.6% from $6.75 in fiscal 2024. Looking ahead, EPS is projected to climb to $7.08, a 9.9% increase year-over-year, for fiscal 2026.

Comparative Stock Performance

WST stock has seen a significant underperformance relative to broader market indices, showing a decrease of 47.7% over the past 52 weeks, while the S&P 500 ($SPX) has gained 2.1%. Moreover, it has also lagged the Health Care Select Sector SPDR Fund (XLV), which dipped 4.7% during the same period.

A significant drop occurred on February 13, when WST shares fell 38.2% post the Q4 results announcement. Despite reporting an adjusted EPS of $1.82, exceeding Wall Street expectations of $1.75, the company’s revenue of $748.8 million surpassed forecasts of $739.6 million. Moreover, WST anticipates its full-year adjusted EPS to fall between $6 and $6.20, alongside projected revenue of $2.88 billion to $2.91 billion.

Brokerage Ratings and Price Targets

Analysts show a bullish consensus on WST stock, with a “Strong Buy” rating prevailing overall. Out of 11 analysts covering the stock, 10 recommend a “Strong Buy,” while one suggests a “Hold.” The average analyst price target stands at $298.33, suggesting a potential upside of 46.4% from current price levels.

On the date of publication, Neha Panjwani did not hold (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article are provided solely for informational purposes. For more information, please view the Barchart Disclosure Policy here.

More news from Barchart

The views and opinions expressed herein are those of the author and do not necessarily reflect those of Nasdaq, Inc.